Chimeric Therapeutics Limited (ASX:CHM)
Australia · Delayed Price · Currency is AUD | Market Cap | 590.64K -94.0% |
| Revenue (ttm) | -189.85K |
| Net Income | -18.81M |
| EPS | -0.61 |
| Shares Out | 118.13M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 511,864 |
| Open | 0.0040 |
| Previous Close | 0.0040 |
| Day's Range | 0.0040 - 0.0050 |
| 52-Week Range | 0.0040 - 0.4000 |
| Beta | 0.64 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 4, 2026 |
About Chimeric Therapeutics
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. It also develops CHM CORE-NK for the treat... [Read more]
Financial Performance
Financial StatementsNews
Chimeric Therapeutics Slides: Investor presentation
Chimeric Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 27, 2026.
Chimeric Therapeutics Transcript: Study update
CHM CDH17 CAR T-cell therapy in phase I/II for colorectal cancer showed 82% stable disease, strong cell expansion and persistence, and manageable safety at high doses. High demand, commercial interest, and promising quality of life improvements support advancing to phase II.
Chimeric Therapeutics Press release: Study update
Chimeric Therapeutics issued a press release on May 31, 2026, disclosing material business information to investors.
Chimeric Therapeutics Transcript: EGM 2026
Shareholders approved major capital raising resolutions, a share consolidation, and discussed governance, capital allocation, and operational shifts to Australia. Key challenges included low retail participation, historical losses, and ASX compliance.
Chimeric Therapeutics Transcript: NWR Virtual Healthcare Conference
Two core cell therapy assets are advancing through late phase I, with strong manufacturing success and promising early clinical outcomes. Regulatory milestones and commercial interest are building, while industry trends show renewed momentum in cell therapy. Key updates on Dose Level 3 and further trial progress are expected soon.
Chimeric Therapeutics Slides: NWR Virtual Healthcare Conference
Chimeric Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 24, 2026.
Chimeric Therapeutics Quarterly report: H1 2026
Chimeric Therapeutics has published its H1 2026 quarterly earnings report on February 26, 2026.
Chimeric Therapeutics Transcript: Investor Update
Phase 1 trials for two cell therapy assets show strong safety, tumor shrinkage, and durable responses, with CHM CDH17 nearing Phase 2 and CHM CORN-K achieving over 50% response rates in AML. Commercial interest and regulatory progress are advancing, with key milestones expected in FY26.
Chimeric Therapeutics Slides: Investor Update
Chimeric Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 7, 2025.